Skip to content
Screener

Reported August 4, 2026 · After market close

Revenue$223.3MMiss by $11.7M
EPS-$0.07Miss by $0.50
Revenue estimate$235.0M
EPS estimate$0.43
“Our consolidated second quarter results reflect mixed performance as the Core Nutritional business delivered results generally in line with our expectations, while our ventures businesses performed below expectations. Specifically, Hiya continued to experience a challenging digital marketing environment, which pressured topline performance, subscriber growth, and margins. Additionally, Rise Wellness experienced a packaging-related disruption that impacted its commercial execution during the quarter. While we believe that these challenges for Hiya and Rise are temporary, and both companies remain well positioned to execute their growth strategies, we now expect net sales for these businesses during the full year to be below our prior expectations and are updating our outlook accordingly.”
Kevin Guest

Next report

Oct 28, 2026 (In 3 weeks)
Revenue estimate$219.0M
EPS estimate$0.11

Financials

Q2 2026

Income statement

See full
Revenue$223.3M-5.3%
Gross profit$174.9M-5.8%
Operating income-$20.0M-220%
Net income-$21.4M-321%
EPS (diluted)-$1.16-323%

Balance sheet

See full
Cash & equivalents$171.5M+11.3%
Total equity$526.3M-0.9%
Total assets$703.2M-4.3%

Cash flow

See full
Operating cash flow$23.3M+90.9%
CapEx$3.2M-37.2%
Free cash flow$20.2M+180%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$265.51M-47.0%
P/S0.3×-0.3×

Profitability

See full
Gross margin77.4%-2.5pp
Operating margin-0.1%-6.4pp

Returns & leverage

See full
Current ratio2.7×+0.5×

Segments

By geography

See full
Greater China$114.6M+1.3%
Americas and Europe$66.1M-8.9%
Southeast Asia Pacific$28.7M-12.7%
North Asia$13.8M-19.5%

By segment

See full
Core Nutritional$191.6M—
Hiya$28.3M-16.7%
Rise$3.4M—

FAQ

When did USANA Health Sciences report Q2 2026 earnings?
USANA Health Sciences (USNA) reported Q2 2026 earnings on August 4, 2026 after market close.
What were USANA Health Sciences's Q2 2026 revenue and EPS?
USANA Health Sciences reported revenue of $223.3M and eps of $-0.07 for Q2 2026.
Did USANA Health Sciences beat estimates in Q2 2026?
Revenue missed the consensus estimate of $235.0M by $11.7M. EPS missed the consensus estimate of $0.43 by $0.50.
Where can I find USANA Health Sciences's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000896264-26-000050) and the 10-Q periodic report (0000896264-26-000056) directly on SEC EDGAR. The filing index links above go to sec.gov.